Of the 6474 patients with pancreatic cancer, 27 (0.4%) had BRCA1 alterations, 108 (1.7%) had BRCA2 alterations, 76 (1.2%) had germline ATM alterations, 25 (0.4%) had PALB2 alterations, and 27 (0.4%) had CHEK2 alterations. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.